MIRA Pharmaceuticals Announces Ketamir-2 Outperforms …
23 hours ago · MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic …
1 day ago · Oct. 21, 2024, 05:50 AM. MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin and ...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms …
17 hours ago · The latest preclinical study, conducted using a nerve ligation-induced neuropathy model in female rats, demonstrated that low doses of oral Ketamir-2 provided significant pain relief by Day 15. By Day 22, Ketamir-2 achieved up to 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses. These findings ...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms
1 day ago · Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Fewer Cognitive Side Effects: With the potential to avoid sedation and ...
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2…
Jul 25, 2024 · The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.
MIRA Pharmaceuticals Advances Ketamir-2 Development …
Sep 18, 2024 · MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant...
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising …
Jun 24, 2024 · MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year. This submission will mark a significant milestone in advancing Ketamir-2 toward clinical trials and eventually making it available to patients in need.
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement …
Nov 20, 2023 · Ketamir-2 is a unique patent-pending compound is under investigation to potentially deliver ultra-rapid antidepressant effects as early as four hours after dosing, providing hope for...
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising
Jun 24, 2024 · MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant ...
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 …
Jul 22, 2024 · MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance. New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders.